NeoGenomics, Inc. Stock News

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Tony Zook has officially assumed the role of Chief Executive Officer.

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.

NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitabili...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in several upcoming investor conferences.

NeoGenomics, Inc (NASDAQ:NEO ) Q4 2024 Earnings Conference Call February 18, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Warren Stone - Chief Commercial Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Nate Montgom...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full year results for the period ended December 31, 2024.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Feb. 18, 2025.

NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a recent selloff.